Opthea (OPT) Competitors $3.41 +0.23 (+7.23%) As of 07/3/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OPT vs. AGIO, CGON, KNSA, BEAM, IDYA, IRON, BLTE, CNTA, HRMY, and ADPTShould you be buying Opthea stock or one of its competitors? The main competitors of Opthea include Agios Pharmaceuticals (AGIO), CG Oncology (CGON), Kiniksa Pharmaceuticals International (KNSA), Beam Therapeutics (BEAM), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Harmony Biosciences (HRMY), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry. Opthea vs. Its Competitors Agios Pharmaceuticals CG Oncology Kiniksa Pharmaceuticals International Beam Therapeutics IDEAYA Biosciences Disc Medicine Belite Bio Centessa Pharmaceuticals Harmony Biosciences Adaptive Biotechnologies Agios Pharmaceuticals (NASDAQ:AGIO) and Opthea (NASDAQ:OPT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment. Is AGIO or OPT more profitable? Agios Pharmaceuticals has a net margin of 1,798.26% compared to Opthea's net margin of 0.00%. Opthea's return on equity of 0.00% beat Agios Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Agios Pharmaceuticals1,798.26% -2.75% -2.52% Opthea N/A N/A N/A Does the media prefer AGIO or OPT? In the previous week, Agios Pharmaceuticals had 2 more articles in the media than Opthea. MarketBeat recorded 5 mentions for Agios Pharmaceuticals and 3 mentions for Opthea. Opthea's average media sentiment score of 0.92 beat Agios Pharmaceuticals' score of 0.33 indicating that Opthea is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Opthea 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, AGIO or OPT? Agios Pharmaceuticals has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Opthea has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Do analysts recommend AGIO or OPT? Agios Pharmaceuticals currently has a consensus price target of $58.60, suggesting a potential upside of 66.43%. Opthea has a consensus price target of $1.33, suggesting a potential downside of 60.90%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Agios Pharmaceuticals is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agios Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17 Do insiders and institutionals have more ownership in AGIO or OPT? 56.0% of Opthea shares are held by institutional investors. 4.9% of Agios Pharmaceuticals shares are held by insiders. Comparatively, 3.2% of Opthea shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has better earnings & valuation, AGIO or OPT? Agios Pharmaceuticals has higher revenue and earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgios Pharmaceuticals$36.50M55.87$673.72M$11.243.13Opthea$120K4,373.61-$220.24MN/AN/A SummaryAgios Pharmaceuticals beats Opthea on 8 of the 15 factors compared between the two stocks. Get Opthea News Delivered to You Automatically Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPT vs. The Competition Export to ExcelMetricOptheaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$524.84M$2.91B$5.52B$9.02BDividend YieldN/A2.44%5.24%4.08%P/E RatioN/A20.3027.1920.04Price / Sales4,373.61250.76395.22100.83Price / CashN/A41.7026.2128.59Price / Book-6.097.397.925.55Net Income-$220.24M-$55.04M$3.17B$248.49M7 Day PerformanceN/A2.51%1.79%4.87%1 Month PerformanceN/A-0.21%1.28%6.63%1 Year Performance73.98%3.41%33.32%20.38% Opthea Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPTOpthea0.3642 of 5 stars$3.41+7.2%$1.33-60.9%+80.4%$524.84M$120K0.008Gap UpAGIOAgios Pharmaceuticals3.9556 of 5 stars$35.21-2.4%$58.60+66.4%-17.4%$2.09B$36.50M3.13390CGONCG Oncology2.3347 of 5 stars$26.25-2.4%$58.67+123.5%-17.7%$2.05B$1.14M-17.3861Gap DownKNSAKiniksa Pharmaceuticals International3.3882 of 5 stars$27.95+0.3%$38.80+38.8%+44.4%$2.03B$423.24M-111.80220Positive NewsAnalyst UpgradeBEAMBeam Therapeutics2.4749 of 5 stars$19.18-4.1%$48.75+154.2%-16.9%$2.01B$63.52M-4.16510IDYAIDEAYA Biosciences2.3661 of 5 stars$21.16-4.3%$53.73+153.9%-38.2%$1.94B$7M-5.8980IRONDisc Medicine3.1366 of 5 stars$53.38-2.5%$96.70+81.2%+14.5%$1.90BN/A-13.6230BLTEBelite Bio2.4444 of 5 stars$58.63-1.4%$96.67+64.9%+28.9%$1.89BN/A-43.1110CNTACentessa Pharmaceuticals3.1504 of 5 stars$13.62-3.2%$27.89+104.8%+55.8%$1.88B$6.85M-7.52200HRMYHarmony Biosciences4.8251 of 5 stars$32.24+0.2%$53.63+66.3%+1.4%$1.85B$714.73M12.31200Positive NewsADPTAdaptive Biotechnologies3.4104 of 5 stars$11.74-0.5%$10.57-10.0%+231.6%$1.79B$178.96M-12.23790 Related Companies and Tools Related Companies AGIO Alternatives CGON Alternatives KNSA Alternatives BEAM Alternatives IDYA Alternatives IRON Alternatives BLTE Alternatives CNTA Alternatives HRMY Alternatives ADPT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPT) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPT Stock Alerts